- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04809818
A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects
March 17, 2021 updated by: Lumosa Therapeutics Co., Ltd.
Double-Blind, Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of LT3001 Drug Product and Drug-Drug Interaction in Healthy Adult Subjects
This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy subjects.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is a two-part study.
Part A is double-blind, placebo-controlled, and will examine the safety and PK profiles of multiple doses of LT3001 drug product in healthy subjects.
Part B is open-label and will assess the safety and PK of LT3001 when coadministered with aspirin, clopidogrel, apixaban or dabigatran.
Study Type
Interventional
Enrollment (Anticipated)
64
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kevin Hsiao
- Phone Number: 5707 +886226557918
- Email: kevin_hsiao@lumosa.com.tw
Study Locations
-
-
California
-
Cypress, California, United States, 90630
- Recruiting
- Lumosa Phase 1 Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject's body weight is ≥50 kg and BMI is within the range of 18 to 32
- Subject is a healthy volunteer.
- Subject's PT, aPTT, and TT are within the normal laboratory range.
- Subject is a nonsmoker
Exclusion Criteria:
- Subject has a current or recent history of regular alcohol consumption.
- Subjects who are enrolled in Part B and allergic to acetylsalicylic acid, other salicylates, clopidogrel, thienopyridines (eg, ticlopidine, prasugrel), apixaban or dabigatran.
- Part B Cohort 2 only: subjects who are poor metabolizers of clopidogrel (CYP2C19*2/*2, *2/*3, or *3/*3 genotype)
- Subject has a presence or history of coagulation abnormality.
- Subjects need to receive a surgery or clinical procedures associated with high bleeding risk.
- Subject has a history of minor bleeding episodes, eg, epistaxis, rectal bleeding, gingival bleeding.
- Subject has a history of peptic ulcer or gastrointestinal bleeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Part A - LT3001 Drug Product
Multiple doses of LT3001 administered by intravenous infusion
|
Multiple doses of LT3001 drug product administered by intravenous infusion
Other Names:
|
PLACEBO_COMPARATOR: Part A - Placebo
Multiple doses of Placebo administered by intravenous infusion
|
Multiple doses of Placebo administered by intravenous infusion
Other Names:
|
EXPERIMENTAL: Part B - LT3001 and Aspirin
Multiple doses of LT3001 and Aspirin administered
|
Multiple doses of LT3001 drug product administered by intravenous infusion
Other Names:
Loading and maintenance doses of Aspirin administered by oral
Other Names:
|
EXPERIMENTAL: Part B - LT3001 and Clopidogrel
Multiple doses of LT3001 and Clopidogrel administered
|
Multiple doses of LT3001 drug product administered by intravenous infusion
Other Names:
Loading and maintenance doses of Clopidogrel administered by oral
Other Names:
|
EXPERIMENTAL: Part B - LT3001 and Apixaban
Multiple doses of LT3001 and Apixaban administered
|
Multiple doses of LT3001 drug product administered by intravenous infusion
Other Names:
Multiple doses of Apixaban administered by oral
Other Names:
|
EXPERIMENTAL: Part B - LT3001 and Dabigatran
Multiple doses of LT3001 and Dabigatran administered
|
Multiple doses of LT3001 drug product administered by intravenous infusion
Other Names:
Multiple doses of Dabigatran administered by oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events
Time Frame: 16 days
|
To evaluate the safety and tolerability of LT3001 administered alone or with Aspirin, Clopidogrel, Apixaban, Dabigatran determined by number and severity of adverse events from the time of dosing up to 16 days post-dose.
|
16 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline in coagulation
Time Frame: 16 days
|
To evaluate the safety of LT3001 administered alone or with Aspirin, Clopidogrel, Apixaban, Dabigatran determined by coagulation test from baseline up to 16 days post-dose.
|
16 days
|
Changes from baseline in platelet function test
Time Frame: 16 days
|
To evaluate the safety of LT3001 administered alone or with Aspirin, Clopidogrel, Apixaban, Dabigatran determined by platelet function from baseline up to 16 days post-dose.
|
16 days
|
Plasma PK parameters of LT3001 - Cmax
Time Frame: 10 days
|
Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001.
|
10 days
|
Plasma PK parameters of LT3001 - Tmax
Time Frame: 10 days
|
Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001.
|
10 days
|
Plasma PK parameters of LT3001 - AUC
Time Frame: 10 days
|
Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001.
|
10 days
|
Plasma PK parameters of Aspirin - Cmax
Time Frame: 8 days
|
Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin administered (alone or with LT3001).
|
8 days
|
Plasma PK parameters of Aspirin - Tmax
Time Frame: 8 days
|
Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin administered (alone or with LT3001).
|
8 days
|
Plasma PK parameters of Aspirin - AUC
Time Frame: 8 days
|
Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin administered (alone or with LT3001).
|
8 days
|
Plasma PK parameters of Clopidogrel - Cmax
Time Frame: 10 days
|
Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel administered (alone or with LT3001).
|
10 days
|
Plasma PK parameters of Clopidogrel - Tmax
Time Frame: 10 days
|
Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel administered (alone or with LT3001).
|
10 days
|
Plasma PK parameters of Clopidogrel - AUC
Time Frame: 10 days
|
Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel administered (alone or with LT3001).
|
10 days
|
Plasma PK parameters of Apixaban - Cmax
Time Frame: 8 days
|
Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban administered (alone or with LT3001).
|
8 days
|
Plasma PK parameters of Apixaban - Tmax
Time Frame: 8 days
|
Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban administered (alone or with LT3001).
|
8 days
|
Plasma PK parameters of Apixaban - AUC
Time Frame: 8 days
|
Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban administered (alone or with LT3001).
|
8 days
|
Plasma PK parameters of Dabigatran - Cmax
Time Frame: 8 days
|
Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran administered (alone or with LT3001).
|
8 days
|
Plasma PK parameters of Dabigatran - Tmax
Time Frame: 8 days
|
Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran administered (alone or with LT3001).
|
8 days
|
Plasma PK parameters of Dabigatran - AUC
Time Frame: 8 days
|
Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran administered (alone or with LT3001).
|
8 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Mimi Yeh, PhD, Lumosa Phase 1 Unit
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
March 21, 2021
Primary Completion (ANTICIPATED)
July 1, 2021
Study Completion (ANTICIPATED)
October 19, 2021
Study Registration Dates
First Submitted
March 5, 2021
First Submitted That Met QC Criteria
March 17, 2021
First Posted (ACTUAL)
March 22, 2021
Study Record Updates
Last Update Posted (ACTUAL)
March 22, 2021
Last Update Submitted That Met QC Criteria
March 17, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Stroke
- Ischemic Stroke
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Protease Inhibitors
- Factor Xa Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Aspirin
- Clopidogrel
- Dabigatran
- Apixaban
Other Study ID Numbers
- LT3001-105
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Ischemic Stroke
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Dongzhimen Hospital, BeijingThe Second Hospital of Hebei Medical University; Peking University Third Hospital and other collaboratorsRecruitingStroke, Ischemic | Stroke, Acute | Acute Ischemic StrokeChina
-
University of MiamiTemporarily not availableStroke, Ischemic | Stroke, Acute | Mesenchymal Stem Cells | Acute Ischemic Stroke | Stroke/Brain AttackUnited States
-
The University of Texas Health Science Center,...National Center for Advancing Translational Sciences (NCATS)CompletedAcute Ischemic Stroke (AIS)United States
-
Shanghai Yueyang Integrated Medicine HospitalRecruitingIschemic Stroke, AcuteChina
-
Beijing Tiantan HospitalCompletedIschemic Stroke, AcuteChina
-
Beijing Tiantan HospitalRecruitingIschemic Stroke, AcuteChina
-
Anaconda Biomed S.L.Not yet recruitingAcute Ischemic Stroke From Large Vessel Occlusion
-
Centre Hospitalier Sud FrancilienCompletedAcute Ischemic Stroke Due to Medium-vessel-occlusionFrance
Clinical Trials on LT3001 drug product
-
Lumosa Therapeutics Co., Ltd.UnknownAcute Ischemic StrokeTaiwan, United States
-
Lumosa Therapeutics Co., Ltd.Not yet recruiting
-
Lumosa Therapeutics Co., Ltd.Not yet recruiting
-
Shanghai Pharmaceuticals Holding Co., LtdRecruiting
-
Assistance Publique - Hôpitaux de ParisActive, not recruiting
-
Assistance Publique - Hôpitaux de ParisRecruitingArtemis (DCLRE1C ) Deficient Severe Combined ImmunodeficiencyFrance
-
First Affiliated Hospital of Guangxi Medical UniversityGenmedicn Biopharma Ltd.RecruitingTransfusion-dependent α-ThalassemiaChina
-
Kamau TherapeuticsRecruitingSickle Cell DiseaseUnited States
-
Regenera Pharma LtdWithdrawnPartial Thickness Burn | Second Degree Burn Less Than 5%TBSAIsrael